AKESO(HK:09926) 智通财经网·2025-10-16 02:33Core Viewpoint - 康方生物's innovative bispecific antibody drug, 依沃西, has shown promising results in a Phase III clinical trial for treating advanced squamous non-small cell lung cancer, which has garnered significant attention in the medical community [1] Group 1: Clinical Research Highlights - The Phase III clinical study (AK112-306/HARMONi-6) comparing 依沃西 combined with chemotherapy against替雷利珠单抗 combined with chemotherapy has been accepted by the prestigious medical journal, The Lancet [1] - The results will be presented at the 2025 European Society for Medical Oncology (ESMO) conference, specifically during the Late-Breaking Abstract session and the Presidential Symposium [1] - The lead researcher, Professor 陆舜 from Shanghai Chest Hospital, will deliver an oral presentation showcasing the outstanding results of the head-to-head trial [1] Group 2: Market Reaction - 康方生物's stock price increased by over 8%, currently trading at 130.5 HKD, with a trading volume of 749 million HKD [1]